CDXS Codexis, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · SEC EDGAR에서 보기 ↗ 종가 10월 2, 2026 10-K/10-Q 8월 11, 2026
$1.36
· 52주 범위 %
· 저점 이상
· 고점까지
$0.9652주 저점
$2.9852주 고점
시가총액 (MRQ)
$124M
P/E (TTM)
-4.2
EPS (TTM)
$-0.32
매출 (TTM)
$78M
내 배지
52주 범위
$1–$3
애널리스트 평점
BUY
목표 주가
$6
P/E
-4.2
ROE
-69.4%
순이익률
-39.6%
배지 스트립이 비어 있습니다. 이 페이지의 아무 지표나 고정하세요.
CDXS 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$1.36
시가총액 (MRQ)
$124M
P/E (TTM)
-4.2
EPS (TTM)
$-0.32
매출 (TTM)
$78M
ROE (TTM)
-69.4%
부채/자본 (MRQ)
1.2
52주 범위
$1–$3
CDXS 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
범위
막대
막대 세분성은 선택한 기간에 따라 조정됩니다. 막대의 시가/고가/저가/종가를 보려면 차트에 마우스를 올리세요.
Codexis, Inc. - Common Stock 정보 위키백과 회사 개요
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
History
Codexis is based in Redwood City, CA and was incorporated in 2002. It went public in April 2010 on NASDAQ, and in October, acquired Maxygen's MolecularBreeding technology portfolio.
Pharmaceutical
Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor. It then won a second time in 2010 for its work with Merck & Co. on the active ingredient in Januvia.
Nutrition
In 2017, the company entered a partnership with Tate & Lyle to provide research and development for the production of new ingredients. That same year, Codexis announced a collaboration with Nestle to provide enzymes for metabolic disorders.
Biotherapeutics
In 2017, Codexis developed a recombinant phenylalanine ammonia-lyase (PAL) enzyme, to act as a substitute phenylalanine hydroxylase (PAH) enzyme for people who suffer from phenylketonuria. The enzyme was in-licensed by Nestle Health Sciences.
In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders.
Life science
In June 2020, they announced a partnership with Molecular Assemblies to engineer enzymes for DNA synthesis.
Technology
Codexis uses directed evolution to develop its enzymes. Using this method, scientists genetically engineer genes, then screen the enzymes produced to see if it creates the properties needed for a specific reaction. Their protein engineering platform, called CodeEvolver, uses machine learning and high-throughput experimentation to learn protein sequence changes and their impacts on protein function.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
섹터Healthcare
산업Life Sciences Tools & Services
직원146
국가US
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출$70M2016-12-31 → 2025-12-31
EPS$-0.502019-12-31 → 2025-12-31
잉여현금흐름$-24M2016-12-31 → 2025-12-31
순이익률-39.6%2016-12-31 → 2025-12-31
가치 평가 및 비율
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
| 지표 | 5년 추세 | CDXS | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| P/E (TTM) | -4.25년 평균 ≈-23.0 | ≈-23.0 | · | · | |
| P/S (TTM) | 1.65년 평균 ≈6.7 | ≈6.7 | 4.2 | 저평가 | |
| P/B (MRQ) | 3.85년 평균 ≈5.1 | ≈5.1 | 0.9 | 고평가 | |
| EV / EBITDA (TTM) | -4.9 | · | · | · | |
| 주가 / FCF (TTM) | -10.25년 평균 ≈2.7 | ≈2.7 | · | · | |
| 주가 / 현금 흐름 (TTM) | -11.95년 평균 ≈-27.0 | ≈-27.0 | · | · | |
| EV / 매출 (TTM) | 1.4 | · | · | · | |
| EV / FCF (TTM) | -9.1 | · | · | · | |
| Price / Tangible Book (주가 / 유형 장부 가치) | 2.65년 평균 ≈5.3 | ≈5.3 | · | · |
동종 기업 중앙값은 지표별로 표준화된 기준으로 계산되며, 이 주식에 표시된 TTM/MRQ 기준과 항상 일치하지 않을 수 있습니다.
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
| 지표 | 5년 추세 | CDXS | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 영업이익률 (TTM) | -35.6%5년 평균 ≈-60.4% | ≈-60.4% | -140.7% | 최상위권 | |
| EBITDA 마진 (TTM) | -28.9%5년 평균 ≈-57.2% | ≈-57.2% | -140.7% | 최상위권 | |
| 세전 마진 (TTM) | -39.5%5년 평균 ≈-65.0% | ≈-65.0% | -122.0% | 최상위권 | |
| 순이익률 (TTM) | -39.6%5년 평균 ≈-65.1% | ≈-65.1% | -140.9% | 최상위권 | |
| ROA (TTM) | -23.8%5년 평균 ≈-27.5% | ≈-27.5% | -22.2% | 약함 | |
| ROE (TTM) | -69.4%5년 평균 ≈-59.3% | ≈-59.3% | -34.9% | 약함 | |
| ROIC | -46.1%5년 평균 ≈-44.8% | ≈-44.8% | -40.5% | 약함 |
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
| 지표 | 5년 추세 | CDXS | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 (MRQ) | 1.2 | · | · | · | |
| 유동비율 (MRQ) | 3.15년 평균 ≈3.8 | ≈3.8 | 6.5 | 낮은 유동성 | |
| Quick Ratio (당좌 비율) | 3.15년 평균 ≈3.1 | ≈3.1 | 1.8 | 강한 유동성 | |
| 장기 부채 / 자기 자본 (MRQ) | 1.0 | · | · | · |
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
| 지표 | 5년 추세 | CDXS | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Revenue YoY (매출 YoY) | 18.6%5년 평균 ≈7.6% | ≈7.6% | · | · | |
| Revenue CAGR 3Y (매출 CAGR 3년) | -20.2%5년 평균 ≈-12.3% | ≈-12.3% | · | · | |
| Revenue CAGR 5Y (매출 CAGR 5년) | 0.38% | · | · | · |
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
| 지표 | 5년 추세 | CDXS | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Asset Turnover (자산 회전율) | 0.55년 평균 ≈0.5 | ≈0.5 | 0.4 | 최상위권 | |
| Inventory Turnover (재고 회전율) | 5.25년 평균 ≈12.5 | ≈12.5 | 1.9 | 최상위권 | |
| Revenue / Employee (연간 매출액 ÷ 직원 수(yfinance 보고 인원수). 파생 — 저장된 SEC-XBRL 개념이 아님.) | ≈$482.1K | · | · | · |
가치 · ≈ 5년 평균 · 산업 중앙값 · 중앙값 대비 평가
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
15.7%
다음 실적
11월 04, 2026
| 기간 | 보고서 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|---|
| 2026년 6월 30일 | 8월 11, 2026 | $-0.13 | $-0.14 | 7.7% |
| 2026년 3월 31일 | 5월 12, 2026 | $-0.10 | $-0.14 | 28.3% |
| 2025년 12월 31일 | $0.11 | $-0.04 | 357.0% | |
| 2025년 9월 30일 | $-0.22 | $-0.15 | -45.2% | |
| 2025년 6월 30일 | $-0.16 | $-0.19 | 16.8% | |
| 2025년 3월 31일 | $-0.25 | $-0.24 | -3.3% | |
| 2024년 12월 31일 | $-0.13 | $-0.04 | -251.4% |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70M | $59M | $70M | $139M | $105M | $69M | $68M | $61M | $50M | $49M | $42M | $35M | |
| Cost of Revenue | $9M | $16M | $13M | $38M | $22M | $14M | $16M | $13M | $14M | $10M | $7M | $10M | |
| R&D Expense | $52M | $46M | $59M | $80M | $56M | $44M | $34M | $30M | $30M | $22M | $21M | $23M | |
| SG&A Expense | $47M | $55M | $53M | $52M | $49M | $35M | $32M | $29M | $29M | $25M | $22M | $22M | |
| Operating Expenses | $112M | $118M | $138M | $173M | $127M | $93M | $81M | $72M | $73M | $57M | $50M | $54M | |
| Operating Income | $-42M | $-59M | $-68M | $-35M | $-23M | $-24M | $-13M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Interest Income | $3M | $4M | $4M | $1M | $459.0K | $405.0K | $1M | $671.0K | $147.0K | $60.0K | $19.0K | $18.0K | |
| Other Non-op | $-5M | $-10M | $-12M | $124.0K | $1M | $-156.0K | $-656.0K | $-291.0K | $-92.0K | $-94.0K | · | · | |
| Pretax Income | $-44M | $-65M | $-76M | $-33M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Income Tax | $47.0K | $34.0K | $69.0K | $276.0K | $189.0K | $339.0K | $17.0K | $-37.0K | $81.0K | $-40.0K | $-338.0K | $-256.0K | |
| Net Income | $-44M | $-65M | $-76M | $-34M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| EPS (Basic) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · | |
| EPS (Diluted) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · | |
| Shares (Basic) | 87,142,000 | 73,408,000 | 68,131,000 | 65,344,000 | 64,568,000 | 59,360,000 | 56,525,000 | · | · | · | · | · | |
| Shares (Diluted) | 87,142,000 | 73,408,000 | 68,131,000 | 65,344,000 | 64,568,000 | 59,360,000 | 56,525,000 | · | · | · | · | · | |
| EBITDA | $-36M | $-54M | $-68M | $-35M | $-23M | $-24M | $-13M | $-11M | $-23M | $-9M | $-8M | $-19M |
대차대조표
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51M | $19M | $65M | $114M | $117M | $149M | $90M | $53M | $31M | $19M | $23M | $26M | |
| Short-term Investments | $27M | $54M | $0 | · | · | · | · | · | · | · | · | · | |
| Receivables | · | · | $10M | $32M | $25M | $14M | $9M | $12M | $11M | $6M | $7M | $4M | |
| Inventory | $2M | $2M | $3M | $2M | $1M | $964.0K | $371.0K | $589.0K | $1M | $825.0K | $992.0K | $1M | |
| Prepaid Expense | $6M | $4M | $5M | $5M | $6M | $3M | $3M | $1M | $984.0K | $1M | $1M | $1M | |
| Other Current Assets | $500.0K | $500.0K | $600.0K | $700.0K | · | · | · | · | · | · | · | · | |
| Current Assets | $97M | $99M | $93M | $163M | $162M | $184M | $114M | $68M | $45M | $27M | $33M | $33M | |
| PP&E (Net) | $13M | $14M | $15M | $23M | $21M | $10M | $6M | $5M | $3M | $2M | $3M | $4M | |
| PP&E (Gross) | $58M | $55M | $55M | $62M | $57M | $43M | $40M | $38M | $35M | $34M | $35M | $37M | |
| Accum. Depreciation | $45M | $41M | $39M | $40M | $36M | $33M | $33M | $33M | $32M | $32M | $32M | $31M | |
| Goodwill | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Intangibles | · | · | · | · | · | · | · | · | · | $0 | $3M | $6M | |
| Other Non-current Assets | $883.0K | $1M | $1M | $350.0K | $276.0K | $294.0K | $178.0K | $1M | $302.0K | $259.0K | $310.0K | $294.0K | |
| Total Assets | $148M | $149M | $137M | $250M | $246M | $222M | $149M | $79M | $54M | $36M | $45M | $48M | |
| Accounts Payable | $2M | $3M | $6M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $5M | |
| Accrued Liabilities | $3M | $6M | $5M | $15M | $13M | $10M | $7M | $5M | $4M | $2M | $2M | $3M | |
| Current Liabilities | $25M | $24M | $36M | $49M | $33M | $25M | $15M | $18M | $25M | $12M | $15M | $14M | |
| Capital Leases | $30M | $28M | $12M | $38M | $44M | $22M | $25M | $61.0K | $302.0K | · | · | · | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $3M | |
| Total Liabilities | $97M | $82M | $50M | $106M | $82M | $52M | $44M | $23M | $29M | $17M | $22M | · | |
| Long-term Debt | $40M | $29M | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $40M | $29M | · | · | · | · | · | · | $302.0K | · | · | · | |
| Common Stock | $9.0K | $8.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | |
| Paid-in Capital | $657M | $630M | $584M | $566M | $552M | $537M | $448M | $387M | $340M | $311M | $306M | $302M | |
| Retained Earnings | $-607M | $-563M | $-498M | $-421M | $-388M | $-366M | $-342M | $-330M | $-315M | $-292M | $-284M | $-276M | |
| AOCI | $8.0K | $52.0K | $0 | · | · | · | · | $0 | $-472.0K | $0 | $405.0K | $-142.0K | |
| Stockholders' Equity | $51M | $67M | $87M | $145M | $164M | $170M | $106M | $56M | $25M | $19M | $23M | $26M | |
| Liabilities + Equity | $148M | $149M | $137M | $250M | $246M | $222M | $149M | $79M | $54M | $36M | $45M | $48M | |
| Shares Outstanding | 90,478,000 | 81,850,000 | 69,905,000 | 65,811,000 | 65,109,000 | 64,283,000 | 58,877,000 | 54,065,000 | 48,365,000 | 41,255,000 | 40,343,000 | 39,563,000 |
현금 흐름
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $5M | $5M | $6M | $5M | · | · | · | · | · | · | · | · | |
| Stock-based Comp | $10M | $13M | $10M | $15M | $12M | $8M | $7M | $8M | $7M | $6M | $5M | $5M | |
| Deferred Tax | $-3.0K | $-2.0K | $0 | $-7.0K | $-9.0K | $-8.0K | $-6.0K | $-29.0K | $12.0K | $-31.0K | $-330.0K | $110.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $0 | $3M | $3M | $3M | |
| Restructuring | $3M | $0 | $3M | $3M | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $10M | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-19M | $-49M | $-53M | $11M | $-14M | $-16M | $-13M | $-14M | $-9M | $-2M | $-433.0K | $321.0K | |
| CapEx | $4M | $4M | $4M | $8M | $14M | $4M | $4M | $3M | $985.0K | $888.0K | $1M | $302.0K | |
| Investing Cash Flow | $24M | $-57M | $-5M | $-14M | $-21M | $-6M | $-4M | $-3M | $-983.0K | $-846.0K | $-1M | $5M | |
| Debt Issued | $10M | $30M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $10M | $30M | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $17M | $31M | $9M | $0 | $0 | $86M | $0 | $37M | $24M | $0 | $0 | $9.0K | |
| Net Stock Activity | $17M | $31M | $9M | $0 | $0 | $86M | $50M | · | $24M | $0 | $0 | $9.0K | |
| Financing Cash Flow | $28M | $61M | $8M | $-575.0K | $4M | $81M | $54M | $39M | $22M | $-490.0K | $-2M | $-611.0K | |
| Net Change in Cash | $32M | $-46M | $-49M | $-3M | $-32M | $59M | $38M | $22M | $12M | $-3M | $-3M | $4M | |
| Taxes Paid | · | $17.0K | $194.0K | $100.0K | $102.0K | $312.0K | $5.0K | $5.0K | $32.0K | $5.0K | $8.0K | $15.0K | |
| Free Cash Flow | $-24M | $-54M | $-57M | $3M | $-28M | $-20M | $-16M | $-17M | $-10M | $-4M | $-2M | $19.0K |
수익성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -59.3% | -98.6% | -97.0% | -25.2% | -21.7% | -34.6% | -18.3% | -18.6% | -45.9% | -17.5% | -18.6% | -54.1% | |
| Net Margin | -62.5% | -110.0% | -108.7% | -24.2% | -20.3% | -34.8% | -17.4% | -17.9% | -46.0% | -17.5% | -18.1% | -54.0% | |
| Pretax Margin | -62.4% | -109.9% | -108.6% | -24.0% | -20.1% | -34.3% | -17.4% | -18.0% | -45.8% | -17.6% | -18.9% | -54.7% | |
| EBITDA Margin | -51.8% | -90.3% | -97.0% | -25.2% | -21.7% | -34.6% | -18.3% | -18.6% | -45.9% | -17.5% | -18.6% | -54.1% | |
| ROA | -29.6% | -45.7% | -39.4% | -13.5% | -9.1% | -13.0% | -10.4% | -16.4% | -51.5% | -21.3% | -16.3% | -35.7% | |
| ROE | -82.8% | -93.0% | -85.6% | -22.5% | -12.8% | -18.4% | -11.5% | -19.6% | -98.6% | -40.8% | -30.8% | -56.3% | |
| ROIC | -46.1% | -61.1% | -78.7% | -24.3% | -13.9% | -14.3% | -11.9% | -20.0% | -92.8% | -44.6% | -32.5% | -71.7% |
유동성 및 지급능력
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 4.2 | 2.6 | 3.3 | 4.9 | 7.4 | 7.4 | 3.8 | 1.8 | 2.2 | 2.2 | 2.4 | |
| Quick Ratio | 3.1 | 3.1 | 2.1 | 3.0 | 4.2 | 6.5 | 6.5 | 3.6 | 1.7 | 2.0 | 2.1 | 2.2 | |
| Debt / Equity | 0.8 | 0.4 | · | · | · | · | · | · | 0.0 | · | · | · | |
| LT Debt / Equity | 0.8 | 0.4 | · | · | · | · | · | · | 0.0 | · | · | · |
효율성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.6 | 0.4 | 0.4 | 0.6 | 0.9 | 1.1 | 1.2 | 0.9 | 0.7 | |
| Inventory Turnover | 5.2 | 7.3 | 5.4 | 23.9 | 20.9 | 20.6 | 32.6 | 15.5 | 15.4 | 10.7 | 5.5 | 6.7 | |
| Receivables Turnover | · | · | 3.3 | 4.9 | 5.4 | 6.0 | 6.7 | 5.3 | 5.6 | 7.4 | 7.5 | 7.6 |
주당
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.56 | $0.82 | $1.24 | $2.20 | $2.52 | $2.65 | $1.79 | $1.03 | $0.51 | $0.46 | $0.57 | $0.67 | |
| Revenue / Share | $0.81 | $0.81 | $1.03 | $2.12 | $1.62 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.22 | $-0.67 | $-0.77 | $0.17 | $-0.22 | · | · | · | · | · | · | · | |
| Cash / Share | $0.56 | $0.24 | $0.93 | $1.73 | $1.79 | $2.32 | $1.54 | $0.97 | $0.65 | $0.47 | $0.58 | $0.67 | |
| EPS (TTM) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 | $-0.21 | · | · | · | · | · |
성장률
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 18.6% | -15.4% | -49.4% | 32.3% | 51.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -20.2% | -17.3% | 0.52% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 0.38% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM)
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $70M | $59M | $70M | $139M | $105M | $69M | $68M | $61M | $50M | $49M | $42M | $35M | |
| Net Income TTM | $-44M | $-65M | $-76M | $-34M | $-21M | $-24M | $-12M | $-11M | $-23M | $-9M | $-8M | $-19M | |
| Market Cap | $147M | $390M | $213M | $307M | $2.04B | $1.40B | $941M | $912M | $404M | $190M | $171M | $100M | |
| Enterprise Value | $109M | $346M | · | · | · | · | · | · | $373M | · | · | · | |
| P/E | -3.3 | -5.4 | -2.7 | -9.1 | -94.8 | -54.6 | -76.1 | · | · | · | · | · | |
| P/S | 2.1 | 6.6 | 3.0 | 2.2 | 19.4 | 20.3 | 13.8 | 15.0 | 8.1 | 3.9 | 4.1 | 2.8 | |
| P/B | 2.9 | 5.8 | 2.5 | 2.1 | 12.4 | 8.2 | 8.9 | 16.2 | 16.5 | 9.9 | 7.5 | 3.8 | |
| P / Tangible Book | 3.1 | 6.1 | 2.5 | 2.2 | 12.6 | 8.4 | · | · | · | · | · | · | |
| P / Cash Flow | -7.6 | -7.9 | -4.1 | 27.2 | -142.7 | -85.2 | -75.0 | -64.7 | -46.1 | -70.3 | -394.1 | 310.6 | |
| P / FCF | -6.2 | -7.3 | -3.7 | 103.0 | -72.5 | -69.4 | -57.8 | -54.1 | -41.4 | -52.9 | -104.6 | 5247.3 | |
| EV / EBITDA | -3.0 | -6.5 | · | · | · | · | · | · | -16.2 | · | · | · | |
| EV / FCF | -4.6 | -6.4 | · | · | · | · | · | · | -38.3 | · | · | · | |
| EV / Revenue | 1.6 | 5.8 | · | · | · | · | · | · | 7.5 | · | · | · | |
| Earnings Yield | -30.7% | -18.7% | -36.7% | -10.9% | -1.1% | -1.8% | -1.3% | · | · | · | · | · |
손익계산서
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $15M | $39M | $9M | $15M | $8M | $21M | $13M | $8M | $17M | $27M | $9M | $21M | $13M | $30M | $34M | |
| Cost of Revenue | $4M | $2M | $2M | $2M | $2M | $3M | $4M | $4M | $3M | $5M | $3M | $2M | $3M | $5M | $8M | $10M | |
| R&D Expense | $12M | $11M | $12M | $14M | $14M | $13M | $12M | $12M | $11M | $11M | $11M | $14M | $17M | $17M | $20M | $22M | |
| SG&A Expense | $11M | $10M | $11M | $11M | $12M | $12M | $13M | $14M | $16M | $13M | $12M | $12M | $13M | $15M | $12M | $13M | |
| Operating Expenses | $26M | $23M | $28M | $28M | $28M | $28M | $29M | $29M | $31M | $29M | $26M | $41M | $34M | $37M | $44M | $45M | |
| Operating Income | $-11M | $-8M | $11M | $-19M | $-13M | $-20M | $-7M | $-17M | $-23M | $-12M | $282.0K | $-32M | $-13M | $-24M | $-13M | $-11M | |
| Interest Income | $535.0K | $665.0K | $656.0K | $634.0K | $584.0K | $751.0K | $940.0K | $849.0K | $972.0K | $909.0K | $906.0K | $1M | $1M | $1M | $823.0K | $436.0K | |
| Other Non-op | $-1M | $-1M | $-2M | $-1M | $-984.0K | $-942.0K | $-4M | $-5M | $-985.0K | $-516.0K | $-8M | $-4M | $-9.0K | $-25.0K | $-26.0K | $216.0K | |
| Pretax Income | $-12M | $-9M | $10M | $-20M | $-13M | $-21M | $-10M | $-21M | $-23M | $-11M | $-7M | $-35M | $-12M | $-23M | $-12M | $-10M | |
| Income Tax | $10.0K | $36.0K | $18.0K | $8.0K | $10.0K | $11.0K | $4.0K | $10.0K | $10.0K | $10.0K | $35.0K | $9.0K | $9.0K | $16.0K | $151.0K | $8.0K | |
| Net Income | $-12M | $-9M | $10M | $-20M | $-13M | $-21M | $-10M | $-21M | $-23M | $-12M | $-7M | $-35M | $-12M | $-23M | $-13M | $-10M | |
| EPS (Basic) | $-0.13 | $-0.10 | $0.13 | $-0.22 | $-0.16 | $-0.25 | $-0.12 | $-0.29 | $-0.32 | $-0.16 | $-0.11 | $-0.50 | $-0.17 | $-0.34 | $-0.19 | $-0.15 | |
| EPS (Diluted) | $-0.13 | $-0.10 | $0.13 | $-0.22 | $-0.16 | $-0.25 | $-0.12 | $-0.29 | $-0.32 | $-0.16 | $-0.11 | $-0.50 | $-0.17 | $-0.34 | $-0.19 | $-0.15 | |
| Shares (Basic) | 91,053,000 | 90,768,000 | · | 90,251,000 | 85,389,000 | 82,410,000 | · | 72,032,000 | 70,376,000 | 69,854,000 | · | 69,466,000 | 67,573,000 | 65,931,000 | · | 65,426,000 | |
| Shares (Diluted) | 91,053,000 | 90,768,000 | · | 90,251,000 | 85,389,000 | 82,410,000 | · | 72,032,000 | 70,376,000 | 69,854,000 | · | 69,466,000 | 67,573,000 | 65,931,000 | · | 65,426,000 | |
| EBITDA | $-11M | · | · | $-19M | $-13M | $-19M | · | $-17M | $-23M | $-12M | · | $-32M | $-13M | $-24M | · | $-11M |
대차대조표
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27M | $37M | $51M | $25M | $27M | $18M | $19M | $37M | $19M | $58M | $65M | $75M | $92M | $103M | $114M | $109M | |
| Short-term Investments | $28M | $29M | $27M | $33M | $40M | $41M | $54M | $53M | $55M | $27M | · | · | · | · | · | · | |
| Inventory | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Prepaid Expense | $3M | $4M | $6M | $5M | $3M | $4M | $4M | $3M | $3M | $5M | · | $5M | $4M | $5M | · | $5M | |
| Other Current Assets | $500.0K | $400.0K | $500.0K | $500.0K | $100.0K | $500.0K | $500.0K | $300.0K | $900.0K | $500.0K | · | · | · | · | · | · | |
| Current Assets | $72M | $80M | $97M | $76M | $89M | $78M | $99M | $113M | $91M | $108M | · | $103M | $120M | $130M | · | $146M | |
| PP&E (Net) | $12M | $13M | $13M | $14M | $15M | $16M | $14M | $13M | $14M | $15M | · | $15M | $23M | $24M | · | $23M | |
| PP&E (Gross) | $59M | $59M | $58M | $58M | $58M | $57M | $55M | $54M | $54M | $55M | · | $54M | $66M | $65M | · | $63M | |
| Accum. Depreciation | $47M | $46M | $45M | $44M | $43M | $42M | $41M | $41M | $40M | $40M | · | $39M | $42M | $41M | · | $39M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $3M | $3M | $3M | $3M | |
| Other Non-current Assets | $1M | $994.0K | $883.0K | $912.0K | $950.0K | $967.0K | $1M | $2M | $2M | $1M | · | $726.0K | $498.0K | $415.0K | · | $208.0K | |
| Total Assets | $120M | $129M | $148M | $124M | $138M | $129M | $149M | $148M | $132M | $150M | · | $154M | $207M | $218M | · | $235M | |
| Accounts Payable | $3M | $2M | $2M | $2M | $1M | $6M | $3M | $4M | $4M | $3M | · | $3M | $4M | $4M | · | $3M | |
| Accrued Liabilities | $3M | $3M | $3M | $3M | $3M | $5M | $6M | $7M | $5M | $5M | · | $9M | $7M | $8M | · | $13M | |
| Current Liabilities | $24M | $15M | $25M | $18M | $15M | $21M | $24M | $35M | $31M | $29M | · | $38M | $36M | $38M | · | $32M | |
| Capital Leases | $28M | $29M | $30M | $26M | $27M | $27M | $28M | $9M | $10M | $11M | · | $13M | $35M | $37M | · | $40M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Total Liabilities | $87M | $86M | $97M | $85M | $83M | $79M | $82M | $75M | $71M | $70M | · | $63M | $83M | $92M | · | $81M | |
| Long-term Debt | $41M | $40M | $40M | $40M | $39M | $29M | · | $29M | $28M | $28M | · | · | · | · | · | · | |
| Total Debt | $41M | · | · | $40M | $39M | $29M | · | $29M | $28M | $28M | · | · | · | · | · | · | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Paid-in Capital | $660M | $659M | $657M | $655M | $652M | $633M | $630M | $626M | $593M | $588M | · | $582M | $580M | $570M | · | $563M | |
| Retained Earnings | $-627M | $-615M | $-607M | $-616M | $-597M | $-583M | $-563M | $-552M | $-532M | $-509M | · | $-490M | $-455M | $-444M | · | $-409M | |
| AOCI | $-13.0K | $-11.0K | $8.0K | $12.0K | $-3.0K | $14.0K | $52.0K | $126.0K | $-23.0K | $-16.0K | · | · | · | · | · | · | |
| Stockholders' Equity | $33M | $43M | $51M | $39M | $56M | $50M | $67M | $73M | $61M | $79M | $87M | $92M | $124M | $126M | $145M | $154M | |
| Liabilities + Equity | $120M | $129M | $148M | $124M | $138M | $129M | $149M | $148M | $132M | $150M | · | $154M | $207M | $218M | · | $235M | |
| Shares Outstanding | 91,388,000 | 90,894,000 | 90,478,000 | 90,281,000 | 90,254,000 | 82,841,000 | 81,850,000 | 81,376,000 | 70,914,000 | 70,554,000 | · | 69,827,000 | 69,804,000 | 66,696,000 | · | 65,613,000 |
현금 흐름
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | · | · | · | |
| Stock-based Comp | $2M | $1M | $2M | $3M | $3M | $2M | $3M | $3M | $5M | $3M | $2M | $2M | $3M | $3M | $3M | $5M | |
| Restructuring | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $3M | $72.0K | $72.0K | $3M | $0 | |
| Other Non-cash | · | · | · | · | · | $3M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-13M | $20M | $-8M | $-18M | $-14M | $-16M | $-13M | $-12M | $-8M | $-11M | $-16M | $-16M | $-9M | $5M | $20M | |
| CapEx | $898.0K | $176.0K | $520.0K | $182.0K | $3M | $1M | $2M | $1M | $395.0K | $1M | $-380.0K | $678.0K | $2M | $3M | $-33.0K | $1M | |
| Investing Cash Flow | $175.0K | $-1M | $6M | $6M | $-367.0K | $12M | $-3M | $2M | $-27M | $-29M | $1M | $-1M | $-2M | $-3M | $33.0K | $-1M | |
| Debt Issued | · | · | $0 | $0 | $10M | $0 | $0 | $0 | $0 | $30M | $0 | $0 | $0 | $0 | · | · | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $30M | · | · | · | · | · | · | |
| Stock Issued | · | · | $-1.0K | $0 | · | · | $-1.0K | $31M | $0 | $0 | $0 | $0 | $7M | $2M | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $2M | · | · | |
| Financing Cash Flow | $66.0K | $-14.0K | $180.0K | $-111.0K | $27M | $1M | $1M | $30M | $-197.0K | $29M | $0 | $-108.0K | $7M | $1M | $339.0K | $133.0K | |
| Net Change in Cash | $-9M | $-14M | $26M | $-1M | $8M | $-944.0K | $-18M | $19M | $-39M | $-7M | $-10M | $-18M | $-11M | $-11M | $5M | $19M | |
| Taxes Paid | · | · | · | · | · | $0 | · | · | · | $17.0K | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-15M | · | · | · | $-9M | · | · | · | $-12M | · | · |
수익성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -75.3% | · | · | -220.3% | -83.9% | -271.6% | · | -129.0% | -284.9% | -69.6% | · | -345.6% | -59.2% | -182.3% | · | -30.9% | |
| Net Margin | -80.5% | · | · | -228.1% | -86.6% | -274.3% | · | -160.8% | -285.2% | -67.4% | · | -376.3% | -54.0% | -174.2% | · | -29.0% | |
| Pretax Margin | -80.4% | · | · | -228.0% | -86.5% | -274.1% | · | -160.8% | -285.1% | -67.3% | · | -376.2% | -54.0% | -174.1% | · | -29.0% | |
| EBITDA Margin | -75.3% | · | · | -220.3% | -83.9% | -255.8% | · | -129.0% | -284.9% | -69.6% | · | -345.6% | -59.2% | -182.3% | · | -30.9% | |
| ROA | -9.3% | · | · | -14.4% | -9.8% | -14.9% | · | -13.6% | -13.4% | -6.3% | · | -17.9% | -5.2% | -10.0% | · | -4.3% | |
| ROE | -27.1% | · | · | -35.0% | -22.7% | -32.1% | · | -25.0% | -24.5% | -11.2% | · | -28.4% | -8.1% | -15.9% | · | -6.2% | |
| ROIC | -15.2% | · | · | -24.2% | -13.6% | -26.0% | · | -16.2% | -25.3% | -11.1% | · | -35.0% | -10.2% | -18.8% | · | -6.9% |
유동성 및 지급능력
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | · | · | 4.1 | 5.8 | 3.7 | · | 3.2 | 3.0 | 3.7 | · | 2.7 | 3.4 | 3.4 | · | 4.6 | |
| Quick Ratio | 2.3 | · | · | 3.2 | 4.4 | 2.9 | · | 2.6 | 2.4 | 2.9 | · | 1.9 | 2.6 | 2.7 | · | 3.4 | |
| Debt / Equity | 1.2 | · | · | 1.0 | 0.7 | 0.6 | · | 0.4 | 0.5 | 0.4 | · | · | · | · | · | · | |
| LT Debt / Equity | 1.0 | · | · | 1.0 | 0.7 | 0.6 | · | 0.4 | 0.5 | 0.4 | · | · | · | · | · | · |
효율성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.1 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 2.0 | · | · | 1.2 | 1.0 | 1.3 | · | 2.0 | 1.6 | 2.2 | · | 1.1 | 1.7 | 2.5 | · | 7.2 |
주당
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.36 | · | · | $0.43 | $0.62 | $0.60 | · | $0.90 | $0.87 | $1.12 | · | $1.31 | $1.78 | $1.89 | · | $2.35 | |
| Revenue / Share | $0.16 | · | · | $0.10 | $0.18 | $0.09 | · | $0.18 | $0.11 | $0.24 | · | $0.13 | $0.32 | $0.20 | · | $0.53 | |
| Cash Flow / Share | · | · | · | · | · | $-0.17 | · | · | · | $-0.11 | · | · | · | $-0.14 | · | · | |
| Cash / Share | $0.30 | · | · | $0.28 | $0.30 | $0.22 | · | $0.46 | $0.26 | $0.82 | · | $1.07 | $1.32 | $1.54 | · | $1.66 | |
| EPS (TTM) | $-0.32 | $-0.73 | · | $-0.75 | $-0.82 | $-0.98 | · | $-0.88 | $-1.09 | $-0.94 | · | $-1.20 | $-0.85 | $-0.72 | · | $-0.47 |
가치 평가 (TTM)
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78M | $47M | · | $53M | $57M | $50M | · | $64M | $61M | $74M | · | $74M | $99M | $116M | · | $133M | |
| Net Income TTM | $-31M | $-62M | · | $-64M | $-65M | $-74M | · | $-62M | $-76M | $-65M | · | $-82M | $-57M | $-48M | · | $-31M | |
| Market Cap | $207M | · | · | $220M | $220M | $223M | · | $251M | $220M | $246M | · | $132M | $195M | $276M | · | $398M | |
| Enterprise Value | $192M | · | · | $201M | $193M | $192M | · | $189M | $175M | $189M | · | · | · | · | · | · | |
| P/E | -7.1 | -2.2 | · | -3.3 | -3.0 | -2.7 | · | -3.5 | -2.8 | -3.7 | · | -1.6 | -3.3 | -5.8 | · | -12.9 | |
| P/S | 2.7 | · | · | 4.2 | 3.9 | 4.5 | · | 3.9 | 3.6 | 3.3 | · | 1.8 | 2.0 | 2.4 | · | 3.0 | |
| P/B | 6.3 | · | · | 5.7 | 4.0 | 4.5 | · | 3.4 | 3.6 | 3.1 | · | 1.4 | 1.6 | 2.2 | · | 2.6 | |
| P / Tangible Book | 6.8 | 3.6 | · | 6.1 | 4.1 | 4.7 | · | 3.5 | 3.7 | 3.2 | · | 1.5 | 1.6 | 2.2 | · | 2.6 | |
| P / Cash Flow | · | · | · | · | · | -16.2 | · | · | · | -31.6 | · | · | · | -30.0 | · | · | |
| EV / Revenue | 2.5 | · | · | 3.8 | 3.4 | 3.9 | · | 2.9 | 2.9 | 2.5 | · | · | · | · | · | · | |
| Earnings Yield | -14.2% | -44.8% | · | -30.7% | -33.6% | -36.4% | · | -28.6% | -35.2% | -26.9% | · | -63.5% | -30.4% | -17.4% | · | -7.8% |
최신 기간은 왼쪽에 · null 값은 ·로 표시
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 매출 | $70M | $59M | $70M | $139M | $105M |
| 영업이익률 % | -59.3% | -98.6% | -97.0% | -25.2% | -21.7% |
| 순이익 | $-44M | $-65M | $-76M | $-34M | $-21M |
| 희석 EPS | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | 0.8 | 0.4 | · | · | · |
| 유동비율 | 3.8 | 4.2 | 2.6 | 3.3 | 4.9 |
| 당좌 비율 | 3.1 | 3.1 | 2.1 | 3.0 | 4.2 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-24M | $-54M | $-57M | $3M | $-28M |
기관 투자자 (13F) 155개의 제출자 · $154.0M 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
보유자
155
보유 가치
$154.0M
신규 포지션
29
청산 포지션
11
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 29 (-4 이전 분기 대비) | 11 (-10 이전 분기 대비) | 61 (+13 이전 분기 대비) | 36 (+4 이전 분기 대비) | +3.0M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| BlackRock, Inc. | $16,462,635 | 7,284,352 | 10.69% | 주식 |
| Opaleye Management Inc. | $15,334,100 | 6,785,000 | 9.96% | 주식 |
| Aberdeen Group plc | $15,300,096 | 6,769,954 | 9.94% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $12,541,054 | 5,549,139 | 8.15% | 주식 |
| Telemark Asset Management, LLC | $8,692,889 | 3,846,411 | 5.65% | 주식 |
| AMERIPRISE FINANCIAL INC | $8,609,334 | 3,809,440 | 5.59% | 주식 |
| Nantahala Capital Management, LLC | $8,189,365 | 3,623,613 | 5.32% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8,174,666 | 3,617,109 | 5.31% | 주식 |
| VANGUARD GROUP INC | $8,054,714 | 4,941,542 | 5.23% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $4,887,990 | 2,162,393 | 3.17% | 주식 |
| STATE STREET CORP | $3,970,400 | 1,756,814 | 2.58% | 주식 |
| D. E. Shaw & Co., Inc. | $3,032,952 | 1,342,014 | 1.97% | 주식 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $3,006,263 | 1,330,205 | 1.95% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2,954,206 | 1,307,171 | 1.92% | 주식 |
| Assenagon Asset Management S.A. | $2,888,746 | 1,278,206 | 1.88% | 주식 |
| AQR CAPITAL MANAGEMENT LLC | $1,910,675 | 845,431 | 1.24% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $1,574,314 | 696,599 | 1.02% | 주식 |
| NORTHERN TRUST CORP | $1,543,444 | 682,940 | 1.00% | 주식 |
| FRANKLIN RESOURCES INC | $1,533,726 | 678,640 | 1.00% | 주식 |
| MORGAN STANLEY | $1,467,125 | 649,170 | 0.95% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $1,313,191 | 581,058 | 0.85% | 주식 |
| Man Group plc | $1,278,240 | 565,593 | 0.83% | 주식 |
| Post Resch Tallon Group Inc. | $1,273,460 | 563,478 | 0.83% | 주식 |
| PERKINS CAPITAL MANAGEMENT INC | $1,188,986 | 526,100 | 0.77% | 주식 |
| FMR LLC | $1,081,371 | 478,483 | 0.70% | 주식 |
| GOLDMAN SACHS GROUP INC | $982,929 | 434,924 | 0.64% | 주식 |
| ALGERT GLOBAL LLC | $973,857 | 430,910 | 0.63% | 주식 |
| Nuveen, LLC | $886,524 | 392,267 | 0.58% | 주식 |
| TUDOR INVESTMENT CORP ET AL | $808,910 | 357,925 | 0.53% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $708,690 | 313,386 | 0.46% | 주식 |
| Russell Investments Group, Ltd. | $696,292 | 308,095 | 0.45% | 주식 |
| PLATINUM INVESTMENT MANAGEMENT LTD | $597,689 | 264,464 | 0.39% | 주식 |
| ROYAL BANK OF CANADA | $594,000 | 262,926 | 0.39% | 주식 |
| Potomac Capital Management, Inc. | $587,600 | 260,000 | 0.38% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $547,397 | 242,211 | 0.36% | 주식 |
| XTX Topco Ltd | $543,817 | 240,627 | 0.35% | 주식 |
| BANK OF AMERICA CORP /DE/ | $543,568 | 240,517 | 0.35% | 주식 |
| UBS Group AG | $542,190 | 239,907 | 0.35% | 주식 |
| Bank of New York Mellon Corp | $510,849 | 226,039 | 0.33% | 주식 |
| CITADEL ADVISORS LLC | $432,971 | 191,580 | 0.28% | 주식 |
| Invesco Ltd. | $366,732 | 162,271 | 0.24% | 주식 |
| Cubist Systematic Strategies, LLC | $359,610 | 147,381 | 0.23% | 주식 |
| BARCLAYS PLC | $350,920 | 155,274 | 0.23% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $334,595 | 148,051 | 0.22% | 주식 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $284,552 | 125,908 | 0.18% | 주식 |
| STRS OHIO | $273,460 | 121,000 | 0.18% | 주식 |
| JANE STREET GROUP, LLC | $273,042 | 120,815 | 0.18% | 주식 |
| MARSHALL WACE, LLP | $264,726 | 117,135 | 0.17% | 주식 |
| Stonepine Capital Management, LLC | $247,836 | 109,662 | 0.16% | 주식 |
| RHUMBLINE ADVISERS | $233,449 | 103,301 | 0.15% | 주식 |
행동주의자 및 5% 이상 소유자 3 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| John Nicols | 2021년 2월 16일 | · | 최초 제출 | 수동적 투자 | SEC |
| – I.RS. IDENTIFICATION NO. OF ABOVE PERSON RAÍZEN ENERGIA S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON SHELL BRAZIL HOLDING B.V., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ROYAL DUTCH SHELL PLC, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN S.A. INDUSTRIA E COMÉRCIO, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN INVESTIMENTOS E PARTICIPAÇÕES S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN LIMITED ×2 제출 서류 | 2015년 5월 26일 | · | 최초 제출 | · | SEC |
| – I.RS. IDENTIFICATION NO. OF ABOVE PERSON RAIZEN ENERGIA PARTICIPA Ç Õ ES S.A., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ISPAGNAC PARTICIPA Ç Õ ES LTDA., – I.RS. IDENTIFICATION NO. OF ABOVE PERSON ROYAL DUTCH SHELL PLC, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN S.A. INDUSTRIA E COM É RCIO, – I.RS. IDENTIFICATION NO. OF ABOVE PERSON COSAN LIMITED | 2011년 6월 7일 | · | 최초 제출 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
회사 내부자 44 명의 내부자 · 19 임원 · 22 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Alison Moore | President and CEO | 2026년 2월 23일 A | 250,506 | 0 | 2 | $-20,672 |
| Peter M Strumph | Interim President and CEO | 2012년 6월 1일 A | 60,756 | 0 | 0 | $0 |
| Alan Shaw | President and CEO | 2011년 12월 16일 S | 202,000 | 0 | 0 | $0 |
| Georgia Erbez | Chief Financial Officer and Chief Business Officer | 2026년 2월 23일 A | 66,810 | 0 | 2 | $-20,610 |
| Sriram Ryali | Chief Financial Officer | 2024년 1월 1일 A | 175,791 | 0 | 0 | $0 |
| Gordon Sangster | SVP & Chief Financial Officer | 2019년 3월 21일 M | 134,453 | 0 | 0 | $0 |
| David D O'Toole | SVP & Chief Financial Officer | 2013년 9월 4일 F | 110,687 | 0 | 0 | $0 |
| Brian Paul Dowd | Interim CFO | 2012년 6월 1일 A | 28,310 | 0 | 0 | $0 |
| Robert J Lawson | SVP and CFO | 2011년 5월 11일 P | 44,000 | 0 | 0 | $0 |
| Kevin Norrett | Chief Operating Officer | 2025년 2월 5일 A | 177,327 | 0 | 0 | $0 |
| Stefan Lutz | Chief Scientific Officer | 2026년 2월 23일 A | 130,421 | 0 | 3 | $-17,853 |
| Margaret Nell Fitzgerald | Chief Legal and Compliance Officer | 2024년 1월 1일 A | 133,770 | 0 | 0 | $0 |
| James Lalonde | SVP, R&D | 2019년 5월 14일 M | 133,402 | 0 | 0 | $0 |
| Michael D. Aldridge | Senior Vice President, Corporate & Strategic Development | 2018년 5월 17일 M | 0 | 0 | 0 | $0 |
| Douglas T. Sheehy | EVP, Chief Administrative Officer, General Counsel & Secretary | 2016년 3월 5일 F | 247,617 | 0 | 0 | $0 |
| Matthew Tobin | SVP, Research & Development | 2013년 5월 16일 M | 78,707 | 0 | 0 | $0 |
| David L. Anton | SVP, BioIndustrials | 2013년 2월 10일 F | 93,777 | 0 | 0 | $0 |
| Seufer-Wasserthal Peter | SVP, Pharmaceuticals | 2013년 1월 24일 A | 93,064 | 0 | 0 | $0 |
| Joseph J. Sarret | SVP and CBO | 2012년 3월 7일 A | 74,000 | 0 | 0 | $0 |
| Raymond De Vre | 이사 | 2026년 6월 17일 A | 84,811 | 0 | 2 | $-8,633 |
| Esther Martinborough | 이사 | 2026년 6월 17일 A | 129,036 | 0 | 0 | $0 |
| Christos Richards | 이사 | 2026년 6월 17일 A | 85,133 | 0 | 0 | $0 |
| Cynthia Collins | 이사 | 2026년 6월 17일 A | 112,157 | 0 | 0 | $0 |
| Stephen George Dilly | 이사 | 2026년 6월 17일 A | 727,053 | 0 | 0 | $0 |
| Rahul Singhvi | 이사 | 2026년 6월 17일 A | 137,052 | 0 | 0 | $0 |
| David V Smith | 이사 | 2026년 6월 17일 A | 105,705 | 0 | 0 | $0 |
| PARKER H STEWART | 이사 | 2026년 6월 17일 A | 143,583 | 0 | 0 | $0 |
| Dennis P Wolf | 이사 | 2025년 11월 21일 S | 138,951 | 0 | 1 | $-13,965 |
| Byron L Dorgan | 이사 | 2024년 6월 11일 A | 223,581 | 0 | 0 | $0 |
| Jennifer Aaker | 이사 | 2023년 6월 13일 A | 66,211 | 0 | 0 | $0 |
| John J Nicols | 이사 | 2023년 4월 18일 M | 783,965 | 0 | 0 | $0 |
| Patrick Y Yang | 이사 | 2022년 6월 14일 A | 53,785 | 0 | 0 | $0 |
| Bernard J Kelley | 이사 | 2021년 8월 10일 M | 206,136 | 0 | 0 | $0 |
| Thomas R Baruch | 이사 | 2020년 6월 12일 S | 33,093 | 0 | 0 | $0 |
| Pam P. Cheng | 이사 | 2019년 6월 11일 A | 69,589 | 0 | 0 | $0 |
| Kathleen Sereda Glaub | 이사 | 2019년 6월 11일 A | 68,481 | 0 | 0 | $0 |
| Alexander Karsner | 이사 | 2014년 1월 2일 A | 78,519 | 0 | 0 | $0 |
| Bruce A Pasternack | 이사 | 2010년 8월 24일 P | 10,000 | 0 | 0 | $0 |
| James R Sulat | 이사 | 2010년 4월 27일 J | 5,957,108 | 0 | 0 | $0 |
| Opaleye Management Inc. | 10% 소유주 | 2025년 12월 1일 S | 179,989 | 0 | 27 | $-7,596,890 |
| Brazil Holding B.V. Shell | 10% 소유주 | 2011년 5월 31일 J | 5,573,319 | 0 | 0 | $0 |
| Equilon Enterprises LLC | 10% 소유주 | 2011년 5월 20일 J | 5,573,319 | 0 | 0 | $0 |
| MAXYGEN INC | 10% 소유주 | 2010년 12월 14일 J | 524,643 | 0 | 0 | $0 |
| Dean Ross Taylor JR | · | 2023년 2월 7일 F | 38,554 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
ETF 보유 현황 19 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.42% | 70,133 SH | 2026년 10월 1일 | 일간 |
| IWC · iShares Trust | 0.03% | 288,891 SH | 2026년 9월 11일 | 일간 |
| IBB · iShares Trust | 0.01% | 766,290 SH | 2026년 9월 11일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 496,936 SH | 2026년 8월 19일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.01% | 78,444 SH | 2026년 8월 19일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.01% | 7,738 SH | 2026년 10월 1일 | 일간 |
| IWO · iShares Trust | 0.01% | 696,097 SH | 2026년 9월 11일 | 일간 |
| IWM · iShares Trust | 0.00% | 2,244,630 SH | 2026년 9월 11일 | 일간 |
| RSSL · Global X Funds | 0.00% | 41,308 NS | 2026년 7월 31일 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.00% | 71,469 SH | 2026년 10월 1일 | 일간 |
| DFAS · Dimensional ETF Trust | 0.00% | 52,788 NS | 2026년 7월 31일 | N-PORT |
| IWV · iShares Trust | 0.00% | 17,106 SH | 2026년 9월 3일 | 일간 |
| DFAC · Dimensional ETF Trust | 0.00% | 19,277 NS | 2026년 7월 31일 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 1,729 NS | 2026년 7월 31일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 895,869 SH | 2026년 8월 19일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2,633,770 SH | 2026년 8월 19일 | 일간 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.00% | 9,454 SH | 2026년 8월 19일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 6,744 SH | 2026년 8월 19일 | 일간 |
| IWN · iShares Trust | · | 129,318 SH | 2026년 9월 11일 | 일간 |
CDXS 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
평점 · 13 명의 애널리스트
매수
중앙값 목표
$5.00
+267.6%
4 30.8%
적극 매수
6 46.2%
매수
3 23.1%
보유
0 0.0%
매도
0 0.0%
적극 매도
12개월 목표 주가
7 명의 애널리스트 · 2026-10-01평균 목표 $6.14 +351.7%
← 모든 목표가 하회
현재가 $1.36
저가$2.00
평균$6.14
고가$11.00
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
회계연도 기준, 각 회사의 마지막 회계연도 말 종가 기준 가격입니다.
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| CDXS | $147M | -3.3 | 18.6% | -62.5% | -82.8% | · |
| LAB | $495M | -6.4 | -6.2% | -87.8% | -17.6% | 49.9% |
| QSI | · | · | · | · | · | · |
| LFCR | $249M | -5.3 | 0.47% | -30.0% | -461.3% | 31.3% |
| NAUT | $247M | -4.1 | · | · | -34.9% | · |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| SEER | · | -1.4 | 17.0% | · | · | · |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | · |
| HYFT | · | · | · | -89.7% | -78.9% | 58.8% |
| CIRC | · | · | · | · | · | · |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요. 상단의 전체 기본 정보에서 원하는 행 옆의 +를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
출처: SEC 10-Q 제출 8월 11, 2026